[Form 4] UroGen Pharma Ltd. Insider Trading Activity

Rhea-AI Filing Summary

Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (URGN), sold 10,000 ordinary shares on 08/11/2025 at a weighted-average price of $17.69 per share. After the transaction he directly beneficially owned 148,229 shares. The filing reports the sale under Transaction Code S and notes the shares were sold in multiple trades at prices ranging from $17.63 to $17.76.

No derivative (options, warrants, or convertible) transactions are reported on this Form 4 and the reporting person indicates availability of further breakdown information on request.

Insights

Securities Analyst

TL;DR: Insider sale of 10,000 shares appears routine; no derivative activity reported and direct ownership remains 148,229 shares.

The Form 4 documents a disposition (code S) of 10,000 ordinary shares by Mark Schoenberg at a weighted-average price of $17.69, with individual trade prices between $17.63 and $17.76. The filing shows the seller retains substantial direct ownership (148,229 shares) and discloses no option or other derivative transactions on Table II. From a trading-data perspective this is a clear, single-line insider sale disclosure without additional complex instruments.

Corporate Governance Expert

TL;DR: Disclosure fulfills Section 16 reporting of an insider sale; the filing is straightforward and provides a price-range explanation.

The Form 4 identifies the reporting person as an officer (Chief Medical Officer) and records a sale of 10,000 shares, leaving 148,229 shares beneficially owned direct. The explanatory note clarifies the reported price is a weighted average from multiple transactions and offers to supply per-trade quantities on request. No amendments or additional parties are indicated. The form appears to meet routine disclosure standards for insider transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schoenberg Mark

(Last) (First) (Middle)

400 ALEXANDER PARK DRIVE

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UroGen Pharma Ltd. [ URGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/11/2025		S		10,000	D	$17.69(1)	148,229	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.63 and $17.76. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

	/s/ Jason D. Smith, Attorney-in-Fact	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported for UroGen (URGN)?

Mark Schoenberg sold 10,000 ordinary shares (disposition reported on Form 4) under Transaction Code S.

How many URGN shares does Mark Schoenberg own after the sale?

He directly beneficially owned 148,229 shares following the reported transaction.

At what price were the URGN shares sold?

The shares were sold at a weighted-average price of $17.69, with individual trades ranging from $17.63 to $17.76.

Were any derivative securities (options, warrants) reported in the filing?

No derivatives are reported on Table II of this Form 4.

Who signed the Form 4 filing for Mark Schoenberg?

The form is signed by Jason D. Smith, Attorney-in-Fact on behalf of the reporting person.